Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause

Sarepta Therapeutics’ (SRPT) stock has been hammered in the past week after the company was forced to pause shipments of its top-selling Duchenne muscular dystrophy (DMD) therapy Elevidys — throwing the future of the company into question.

Elevidys netted $821 million of the company’s $1.78 billion in 2024 revenue and contributed to more than 50% of the company’s $513 million in second quarter revenue this year. It’s the company’s top-selling product. It’s why seven analysts have downgraded the stock since Friday, including Bank of America’s Tazeen Ahmad on Wednesday.

Ahmad downgraded the stock to Underperform and revised the firm’s price target to $10 from $20. The stock is currently trading at $13.90 per share and closed down more than 2% on Wednesday.

Sarepta “has requested a meeting with FDA and might have more visibility on length of the pause once FDA responds to their submission for a revised label,” Ahmad wrote in a note to clients. “In short, we think this could impact the Elevidys brand further, limiting uptake following highly focused media attention as well as a renewed chance of Elevidys being removed from the US market.”

Leerink Partners downgraded the stock last week from Outperform to Market Perform. Analyst Joseph Schwartz wrote in a note to clients on Monday that how long the pause lasts is important for future modeling.

“This decision is also roughly aligned with our published SRPT model, which assumes a significant slowing of sales in the third quarter, zero sales in the fourth quarter, and a resumption of shipments in early 2026,” Schwartz wrote. “We lack visibility into how long this pause may last, or what the intermediate scenarios are from here (e.g., a narrower approval).”

The stock now has five Buy, 17 Hold, and four Sell ratings.

The technology to deliver the therapy in Elevidys is at the center of the issue facing the company. A 51-year-old, late-stage patient in a phase 1 trial of a different muscular dystrophy therapy, known only by its trial name, SRP-9004, died from liver toxicity last month, but Sarepta failed to disclose the death — even as it announced it was discontinuing the trial as part of a restructuring last week.

That began the domino effect of downgrades and the stock sell-off as analysts questioned why the company had kept quiet. On a call with investors Friday, CEO Doug Ingram defended his reasoning for not mentioning it.

“We did not discuss this matter in our call on Wednesday because it was neither material nor central to the topics at hand on Wednesday,” Ingram said.